Today: 7 February 2026
Subscribe

Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Gilead Sciences shares rose 2.3% to $140.97 Tuesday, hitting a 52-week high after Medicare named its HIV drug Biktarvy for price negotiations starting in 2028. Trading volume topped 10.5 million shares. CEO Daniel O’Day sold 115,640 shares last week under a pre-set plan. Gilead will report fourth-quarter and full-year results after markets close on Feb. 10.
28 January 2026
···
HCA stock jumps after earnings and a $10B buyback — what to watch before Wednesday’s open

HCA stock jumps after earnings and a $10B buyback — what to watch before Wednesday’s open

HCA Healthcare shares surged 7.1% to $505.84 after the company raised its 2026 profit outlook and approved a new $10 billion share buyback. Fourth-quarter revenue rose 6.7% to $19.51 billion, with net income at $1.88 billion. Investors remain cautious as ACA exchange subsidies expire, potentially reducing patient volumes. The board also declared a $0.78 quarterly dividend, payable March 31.
28 January 2026
··
Coinbase stock in focus: Cantor’s $277 call clashes with UK ad ban as Fed looms

Coinbase stock in focus: Cantor’s $277 call clashes with UK ad ban as Fed looms

Coinbase shares fell 1.2% to $210.83 in after-hours trading Tuesday, despite Cantor Fitzgerald starting coverage with an Overweight rating and a $277 price target. Britain’s ad regulator banned a Coinbase campaign, saying it downplayed crypto risks; Coinbase disputed the ruling. Bitcoin rose 0.7% to $89,313, while Ether gained 2.6%. Coinbase’s next earnings report is pending.
28 January 2026
··
Rocket Lab stock jumps, but Neutron setback keeps investors on edge ahead of February results

Rocket Lab stock jumps, but Neutron setback keeps investors on edge ahead of February results

Rocket Lab shares rose 8% Tuesday before slipping after hours, following a recent Neutron Stage 1 tank rupture that cast uncertainty on the rocket’s launch timeline. The stock traded near $87, up from $80.48, after rebounding from a 9.5% drop Monday. Investors await the late-February earnings call for updates on the Neutron program. The company also secured an $816 million U.S. defense contract.
28 January 2026
···
Fatburger owner FAT Brands files Chapter 11 bankruptcy, pulling Twin Peaks parent Twin Hospitality into court

Fatburger owner FAT Brands files Chapter 11 bankruptcy, pulling Twin Peaks parent Twin Hospitality into court

FAT Brands and affiliate Twin Hospitality filed for Chapter 11 bankruptcy in Houston, citing $1.4 billion in debt and missed interest payments. Court documents show FAT Brands has just $2.1 million in cash. Shares of both companies fell by about a third in late trading. Restaurants, including Fatburger, Johnny Rockets, Twin Peaks, and Smokey Bones, will remain open.
28 January 2026
··
Starbucks stock dips as supply-chain snags and CEO jet policy land ahead of earnings

Starbucks stock dips as supply-chain snags and CEO jet policy land ahead of earnings

Starbucks shares fell 0.6% to $95.72 Tuesday ahead of its fiscal first-quarter earnings report set for Wednesday morning. CEO Brian Niccol is under scrutiny as supply-chain issues persist despite new technology and system upgrades. The company also removed the $250,000 cap on Niccol’s personal use of the corporate jet after a security review. Wall Street analysts adjusted price targets as investors focus on sales and margins.
28 January 2026
··
Carvana stock rises after Wells Fargo target hike, but options traders lean defensive

Carvana stock rises after Wells Fargo target hike, but options traders lean defensive

Carvana shares closed up 0.9% at $477.75 after volatile trading Tuesday. Wells Fargo raised its price target to $525, citing strong retail trends but flagged possible weather-related risks. Options trading showed a surge in put buying ahead of the Fed decision and Carvana’s Feb. 18 earnings. Implied volatility remained high, with puts outnumbering calls by nearly two to one.
28 January 2026
·
Constellation Energy stock closes higher as PJM data-center rule overhaul keeps power prices in focus

Constellation Energy stock closes higher as PJM data-center rule overhaul keeps power prices in focus

Constellation Energy closed up 1.2% at $288.76 Tuesday, after trading between $282.50 and $290.40. PJM Interconnection advanced a fast-track plan for data-center hookups and began talks on a government-backed “backstop” auction for new power capacity. Traders are watching natural-gas volatility and PJM/FERC policy moves. Constellation’s next earnings update is expected Feb. 17.
28 January 2026
··
Elevance Health stock gets hit by Medicare rate surprise — what traders watch before earnings

Elevance Health stock gets hit by Medicare rate surprise — what traders watch before earnings

Elevance Health shares fell 14.3% to $322.92 Tuesday after a Medicare Advantage rate proposal from CMS projected a net average payment increase of just 0.09%, far below Wall Street expectations. The move triggered a broader selloff in health insurer stocks. Investors are awaiting Elevance’s earnings report Wednesday for updates on pricing and costs. CMS will finalize policy milestones in late February and early April.
28 January 2026
··
Roper Technologies stock (ROP) slides after weak 2026 outlook puts Deltek back in focus

Roper Technologies stock (ROP) slides after weak 2026 outlook puts Deltek back in focus

Roper Technologies shares dropped 9.7% to $369.27 in after-hours trading Tuesday after the company issued a 2026 profit and revenue forecast below Wall Street estimates and warned of continued weak demand at its Deltek unit. Stifel downgraded the stock, citing ongoing Deltek softness. Roper reported Q4 revenue up 10% to $2.06 billion and adjusted EPS of $5.21. The company projected 2026 adjusted EPS of $21.30–$21.55.
28 January 2026
·
Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson shares rose 1.3% Tuesday after the FDA approved a Darzalex Faspro combination for newly diagnosed multiple myeloma patients ineligible for stem-cell transplants. The S&P 500 closed at a record high, while healthcare stocks broadly fell after a Medicare payment proposal. The U.S. also named 15 drugs for future Medicare price negotiations, increasing pressure on big pharma.
28 January 2026
···
KLA stock jumps nearly 5% as analysts lift targets ahead of Jan. 29 earnings

KLA stock jumps nearly 5% as analysts lift targets ahead of Jan. 29 earnings

KLA shares rose 4.8% to about $1,616 in after-hours trading Tuesday after Evercore ISI and Wolfe Research raised price targets ahead of Thursday’s earnings. The company projects fiscal Q2 revenue of $3.225 billion and non-GAAP EPS of $8.70, with Zacks’ consensus slightly higher. KLA warned U.S.-China trade tensions could cut sales by up to $350 million over the next five quarters.
28 January 2026
··
1 … 179 180 181 182 183 … 1,631

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop